Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Vorolanib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Vorolanib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Voruciclib |
CDK Inhibitor | Solid Tumour | ||
|
Molecule
Voruciclib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
CDK Inhibitor |
||||
Zalifrelimab |
Anti-CTLA-4 mAb | Solid Tumour | ||
|
Molecule
Zalifrelimab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-CTLA-4 mAb |
||||
Zandelisib |
PI3K Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Zandelisib
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
||||
Zanidatamab |
Anti-HER2 Agent | Solid Tumour (Breast/Gastric) | ||
|
Molecule
Zanidatamab
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
||||
Zidesamtinib |
ROS1-Selective Tyrosine Kinase Inhibitor | Solid Tumour | ||
|
Molecule
Zidesamtinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ROS1-Selective Tyrosine Kinase Inhibitor |
||||
Ziftomenib |
EZH2 / Menin Inhibitor | Hematologic | ||
|
Molecule
Ziftomenib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 / Menin Inhibitor |
||||
Zilovertamab Vedotin |
ADC | Solid Tumour | ||
|
Molecule
Zilovertamab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Zimberelimab |
Anti-PD-1 mAb | Both (Solid & Hematologic) | ||
|
Molecule
Zimberelimab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
||||
Ziv-Aflibercept |
Anti-VEGF / VEGFR Agent | Solid Tumour | ||
|
Molecule
Ziv-Aflibercept
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
||||
Zorifertinib |
EGFR / HER2 Tyrosine Kinase Inhibitor | Solid Tumour | ||
|
Molecule
Zorifertinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
||||
Fulzerasib |
KRAS G12C Covalent Inhibitor | Solid Tumour | ||
|
Molecule
Fulzerasib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
KRAS G12C Covalent Inhibitor |
||||
VorolanibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
VoruciclibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
CDK Inhibitor |
|
ZalifrelimabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-CTLA-4 mAb |
|
ZandelisibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
|
ZanidatamabTargeted Therapy (Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
|
ZidesamtinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ROS1-Selective Tyrosine Kinase Inhibitor |
|
ZiftomenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 / Menin Inhibitor |
|
Zilovertamab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
ZimberelimabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
|
Ziv-AfliberceptTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
|
ZorifertinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
|
FulzerasibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
KRAS G12C Covalent Inhibitor |
|